• Explore /
  • Poster
  • / Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).

Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).

Abstract Poster

Authors

null

Ajai Chari

Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY

Ajai Chari , Saad Zafar Usmani , Maria-Victoria Mateos , Niels Van De Donk , Jonathan L. Kaufman , Philippe Moreau , Albert Oriol Rocafiguera , Torben Plesner , Lotfi Benboubker , Kevin Liu , Peter Hellemans , Tara J. Masterson , Pamela L. Clemens , Andrew Farnsworth , Hareth Nahi , Jesus San-Miguel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies—Plasma Cell Dyscrasia

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT02519452

Citation

J Clin Oncol 36, 2018 (suppl; abstr 8013)

DOI

10.1200/JCO.2018.36.15_suppl.8013

Abstract #

8013

Poster Bd #

22

Abstract Disclosures

Similar Posters

First Author: Hareth Nahi

First Author: Saad Zafar Usmani

First Author: Nizar J. Bahlis

First Author: Cyrille Touzeau